Wasat Mansoor

10.3k total citations · 3 hit papers
98 papers, 3.1k citations indexed

About

Wasat Mansoor is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Wasat Mansoor has authored 98 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 56 papers in Pulmonary and Respiratory Medicine and 36 papers in Epidemiology. Recurrent topics in Wasat Mansoor's work include Gastric Cancer Management and Outcomes (53 papers), Esophageal Cancer Research and Treatment (30 papers) and Neuroendocrine Tumor Research Advances (30 papers). Wasat Mansoor is often cited by papers focused on Gastric Cancer Management and Outcomes (53 papers), Esophageal Cancer Research and Treatment (30 papers) and Neuroendocrine Tumor Research Advances (30 papers). Wasat Mansoor collaborates with scholars based in United Kingdom, United States and Japan. Wasat Mansoor's co-authors include David Cunningham, Stephen Falk, Fareeda Y. Coxon, Ian Chau, Jonathan Wadsley, Gary Middleton, Eric Van Cutsem, Alicia Okines, Kohei Shitara and David Ferry and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Lancet Oncology.

In The Last Decade

Wasat Mansoor

95 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

2013 547 citations Thomas K. Waddell, Ian Chau et al. The Lancet Oncology profile →
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

2013 405 citations Fareeda Y. Coxon, Jonathan Wadsley et al. The Lancet Oncology profile →
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

2017 391 citations Peter Thuss‐Patience, Manish A. Shah et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Wasat Mansoor

Since Specialization

Citations

This map shows the geographic impact of Wasat Mansoor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wasat Mansoor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wasat Mansoor more than expected).

Fields of papers citing papers by Wasat Mansoor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wasat Mansoor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wasat Mansoor. The network helps show where Wasat Mansoor may publish in the future.

Co-authorship network of co-authors of Wasat Mansoor

This figure shows the co-authorship network connecting the top 25 collaborators of Wasat Mansoor. A scholar is included among the top collaborators of Wasat Mansoor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wasat Mansoor. Wasat Mansoor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rare pathogenic NR2F2 (COUP-TFII) variants as potential etiological causes in pediatric patients with congenital heart diseases (CHDs) 2025 ·Hellenic Journal of Cardiology ·Wasat Mansoor, Mohammad Heidari, Mehri Khatami, (unknown), (unknown), Marzieh Araghi	1
2	First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study 2024 ·Journal of Clinical Oncology ·(unknown), Guillermo Méndez, Joseph Chao, Radim Němeček, Kynan Feeney, Eric Van Cutsem, Salah‐Eddin Al‐Batran, Wasat Mansoor, N. Maisey, Roberto Pazo-Cid, Matthew Burge, David Pérez-Callejo, R. William Hipkin, (unknown), Ming Lei, Hao Tang, Satyendra Suryawanshi, Ronan J. Kelly, Niall C. Tebbutt	27
3	Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE 2024 ·ESMO Open ·(unknown), Susanna Slater, Claire Saffery, (unknown), (unknown), Gillian Smith, Maria Aresu, Darina Kohoutová, (unknown), (unknown), Isma Rana, Edward W. Johnston, (unknown), Elizabeth Smyth, Wasat Mansoor, (unknown), Shuan Rao, Ian Chau, Naureen Starling, David Cunningham	4
4	Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial 2023 ·Gastric Cancer ·Michele Ghidini, Howard S. Höchster, Toshihiko Doi, Eric Van Cutsem, Lukas Makris, Osamu Takahashi, Karim A. Benhadji, Wasat Mansoor	1
5	The occurrence and associated risk factors of brain metastases in well differentiated grade 1 and 2 bronchial neuroendocrine tumours: A single centre retrospective analysis of 280 patients 2022 ·Journal of Neuroendocrinology ·(unknown), James Jones, (unknown), Kandadai Rammohan, (unknown), Jamie Weaver, George Papaxoinis, Wasat Mansoor	0
6	Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study 2021 ·Gastric Cancer ·Wasat Mansoor, Hendrik‐Tobias Arkenau, María Alsina, Kohei Shitara, Peter Thuss‐Patience, Sinéad Cuffe, Mikhail Dvorkin, Jae‐Hyun Park, Takayuki Ando, Marc Van den Eynde, Giordano Beretta, Alberto Zaniboni, Toshihiko Doi, Josep Tabernero, David H. Ilson, Lukas Makris, Karim A. Benhadji, Eric Van Cutsem	6
7	Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreatobiliary cancers: A UK study 2020 ·Journal of Cancer Policy ·(unknown), George Papaxoinis, (unknown), (unknown), Alison Backen, David Cunningham, Wasat Mansoor	4
8	LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study 2020 ·Annals of Oncology ·Ken Kato, (unknown), Manan Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, J-P. Metges, Zhouxiao Li, S-B. Kim, (unknown), Wasat Mansoor, SH Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, (unknown), Sukrut Shah, Pooja Bhagia, Lin Shen	98
9	Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours 2019 ·Neuroendocrinology ·George Papaxoinis, (unknown), (unknown), (unknown), Ángela Lamarca, Alison Backen, Daisuke Nonaka, Wasat Mansoor	27
10	The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study 2019 ·Journal of Gastrointestinal Surgery ·George Papaxoinis, Konstantinos Kamposioras, Jamie Weaver, (unknown), (unknown), (unknown), (unknown), (unknown), Alan Anthoney, Wasat Mansoor	12
11	Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas 2019 ·Neuroendocrinology ·Melissa Frizziero, Francesca Spada, Ángela Lamarca, (unknown), Jorge Barriuso, (unknown), Mairéad G. McNamara, Richard Hubner, Wasat Mansoor, Prakash Manoharan, Nicola Fazio, Juan W. Valle	30
12	Prognostic significance of positive circumferential resection margin post neoadjuvant chemotherapy in patients with esophageal or gastro-esophageal junction adenocarcinoma 2018 ·European Journal of Surgical Oncology ·(unknown), George Papaxoinis, (unknown), Jamie Weaver, (unknown), Bilal Alkhaffaf, Simon Galloway, Wasat Mansoor	11
13	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study breakdown → 2017 ·The Lancet Oncology ·Peter Thuss‐Patience, Manish A. Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A. Ajani, Hugo R. Castro, Wasat Mansoor, Hyun Cheol Chung, G. Bodoky, Kohei Shitara, Gail D. Lewis Phillips, T. van der Horst, (unknown), Betsy Althaus, Yoon‐Koo Kang	391
14	68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management 2017 ·Neuroendocrinology ·Ángela Lamarca, D. Mark Pritchard, (unknown), George Papaxoinis, Daisuke Nonaka, Sobhan Vinjamuri, Juan W. Valle, Prakash Manoharan, Wasat Mansoor	10
15	A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB 2017 ·Annals of Oncology ·Jaffer A. Ajani, Anghel Adrian Udrea, Tomasz Sarosiek, (unknown), Carys Morgan, Joanna Pikiel, E. Wójcik, Daniel Swinson, Mano Joseph, Alexander Luft, (unknown), Christophe Tournigand, D. Ferry, Y. Zhang, Amanda Long, (unknown), Ling Gao, John Kauh, Wasat Mansoor	3
16	Carcinoid syndrome: Patient outcomes from a European Neuroendocrine Tumour Society (ENETs) centre of excellence 2017 ·Annals of Oncology ·(unknown), Eitan Amir, (unknown), (unknown), Wasat Mansoor, Richard Hubner, Juan W. Valle, Mairéad G. McNamara	2
17	Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study 2016 ·Annals of Oncology ·Piero Ferollà, (unknown), Tim Meyer, Wasat Mansoor, Julien Mazières, Christine Do Cao, H. Léna, Alfredo Berruti, V. Damiano, Wieneke A. Buikhuisen, (unknown), Neha Singh, (unknown), Gabriella Gislimberti, Kjell Öberg, Éric Baudin	28
18	Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues 2015 ·Drug Design Development and Therapy ·Edward M. Wolin, Barbara Jarząb, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael A. Morse, Paola Tomassetti, Matthias M. Weber, David R. Fogelman, John Ramage, Donald Poon, Brian Gadbaw, Li Jiang, Janice L. Pasieka, Abakar Mahamat, Fredrik Swahn, John Newell‐Price, Wasat Mansoor, Kjell Öberg	150
19	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial breakdown → 2013 ·The Lancet Oncology ·Thomas K. Waddell, Ian Chau, David Cunningham, David González, Alicia Okines, Andrew Wotherspoon, Claire Saffery, Gary Middleton, Jonathan Wadsley, David Ferry, Wasat Mansoor, Tom Crosby, Fareeda Y. Coxon, David A. Smith, Justin S. Waters, Timothy Iveson, Stephen Falk, Sarah Slater, Clare Peckitt, Yolanda Barbáchano	547
20	Elicitation of health state utilities in neuroendocrine tumours 2012 ·Journal of Medical Economics ·Paul Swinburn, (unknown), David Chandiwana, Wasat Mansoor, Andrew Lloyd	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact